Amicus Therapeutics Inc. (FOLD) provided updates and detailed the statistical analysis plan for its second Phase 3 study of the oral small molecule pharmacological chaperone migalastat HCl monotherapy for Fabry patients with amenable mutations Monday morning.
Amicus Therapeutics has spiked sharply to the upside in the last 15 minutes on increased volume and is currently higher by 0.75 at $3.78. The stock has soared to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.